Pitobrutinib generic version price

Pirtobrutinib, trade name Jaypirca, is an innovative targeted therapy drug developed by Eli Lilly and Company of the United States. It is primarily used to treat patients with mantle cell lymphoma (MCL) who have relapsed or been refractory after multiple systemic therapies, including BTK inhibitors. Pitobrutinib, as a non-covalent (reversible) brutinib-sensitive kinase (BTK) inhibitor, blocks the growth and division of lymphoma cells by precisely inhibiting the activity of BTK, thereby effectively controlling the development of the disease.

Pittobrutinib performed well in clinical trials, with significant efficacy and high safety. The drug can extend patients' survival and improve their quality of life. In addition, pitobrutinib has shown therapeutic potential in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), providing a new treatment option for these patients.

It is worth noting that Pitobrutinib received accelerated approval from the US FDA in January 2023, and was subsequently approved by the European Union. During the use of pitobrutinib, patients may experience some adverse reactions, such as fatigue, musculoskeletal pain, diarrhea, etc. However, these side effects are usually temporary and can be well controlled with a doctor's guidance and management. Patients should pay close attention to their physical condition when using this drug and promptly report any discomfort or side effects to their doctor.

At present, there is no Pitobrutinib on the market in China. Therefore, if domestic patients need this drug, they can only choose to purchase it abroad or contact and purchase it through regular overseas medical consulting companies. According to sources, there are original and generic versions of pittobrutinib in overseas markets. Among them, the price of the original 50mg*30 tablets in the United States is as high as about 100,000 yuan, while the price of the generic version in Laos is relatively affordable, about 4,500 yuan. If you have more questions about pitobrutinib, it is recommended to seek answers from professional overseas consulting companies.

xa0

Reference: https://www.drugs.com/pirtobrutinib.html